We believe this issue has no bearing on our proposed acquisition of Guidant. Unfortunately, threats of legal action are commonplace in our industry.
We believe we can close by the end of March.
We continue to believe our $72 (a share) proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time.
We continue to believe our $72 (per share) proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant.
We continue to believe our $72 proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant.
We continue to expect to be in a position to sign a definitive agreement in the first two weeks of January.
We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant.
We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant. I don't think we're going to have anything more to say right now.
We continue to move forward with our due diligence with the goal of reaching a definitive agreement with Guidant.
We factored in the possibility of something like this happening. This news is manageable and does not alter our fundamental belief in Guidant's long-term potential, which is significant and very much intact.
We have brought a lot of companies into the Boston Scientific family and we have never been more confident or enthusiastic about the prospects for a merger.
We should have things re-stocked in a few weeks.
We will recommend changes designed to ensure that the final regulation preserves the fullest possible beneficiary access to innovative technologies and therapies.
We're pleased to close this chapter, and put this matter behind us. We can now direct our full attention to developing our life-saving products and technologies.
We've reviewed the intellectual property issues and are comfortable proceeding with the transaction. We don't expect this issue to impact the transaction.
Diese Website konzentriert sich auf Sprichwörter der schwedischen Sprache. Einige Teile einschließlich der Links sind nicht ins Deutsche übersetzt worden. Diese Links sind hauptsächlich FAQ, verschiedene Informationen und Webseiten, die der Erweiterung der Sammlung dienen.
Diese Website konzentriert sich auf Sprichwörter der schwedischen Sprache. Einige Teile einschließlich der Links sind nicht ins Deutsche übersetzt worden. Diese Links sind hauptsächlich FAQ, verschiedene Informationen und Webseiten, die der Erweiterung der Sammlung dienen.